Judge rejects Trump administration challenge to New York’s ‘Green Light Law’ ...

Ultragenyx Pharmaceutical said on Monday that late-stage studies showed its drug for a type of genetic bone disease failed to ...

BIDMC investigator Mary Bouxsein helped secure FDA approval of bone density imaging as a faster endpoint for osteoporosis ...

New research is putting prunes under scientific scrutiny to determine whether they can slow osteoporosis development during ...

Know your bone health: After 40, especially in postmenopausal women and men with sedentary routines, a bone density scan ...

The first time I realized my bones weren’t quite the silent partners I thought they were, I was reaching for a laundry basket. Not falling off a ladder, not running a marathon, just the laundry. There ...

Ultragenyx Pharmaceutical said on Monday that its ‍experimental drug for a type of genetic bone disease did not meet the main goal ‌in late-stage ‌studies. The company was testing the treatment called ...

At the time, we simply accepted this as 'old age'. Today, we understand that one of the major culprits behind this dramatic ...

CurveBeam AI's (ASX:CVB)  business rationale is simple enough: orthopaedic surgeons can snare a greater share of a ...

New evidence suggests that the risk for fracture increases within months of low-dose prednisone, challenging the idea of a ...

Dr Akbar Niazi Teaching Hospital (ANTH), in collaboration with the Lions Clubs of Rawalpindi–Islamabad and Bardasht, Pakistan, ...

Ultragenyx is developing setrusumab in pediatric and young adult patients across OI sub-types I, III and IV with two late-stage studies: the pivotal Phase 2/3 Orbit study and Phase 3 Cosmic study.